Status:
COMPLETED
Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis
Lead Sponsor:
Novartis
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Topical steroid use may lead to skin deterioration and spider veins. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on ...
Eligibility Criteria
Inclusion
- clinically diagnosed AD
- almost clear to mild AD (local IGA \[target lesions face and cubital areas\] score of 1-3)
- clinically (i.e. to the unaided eye) evident skin atrophy due to long-term topical steroid use
- Dermatophot Score (DPS - composed of skin atrophy and telangiectasia) of 4-6 on at least two target areas
Exclusion
- Phototherapy or systemic therapy known or suspected to have an effect on AD within 4 weeks prior to study entry
- Topical therapy known or suspected to have an effect on AD within 7 days prior to study entry or systemic corticosteroids within 4 weeks prior to study entry
- Clinical conditions other than AD that according to investigator can interfere with the Dermatophot evaluation
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00367393
Start Date
March 1 2006
End Date
December 1 2007
Last Update
February 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Novartis, Germany